secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001213900-23-083645
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q3 revenue $16.3M (+8% YoY); raises 2023 guidance, introduces 2024 outlook
--------------------------------------------------------------------------------

- GAAP net loss per share $(0.17); non-GAAP EPS $0.09 vs $0.07 YoY.
- 2023 revenue guidance raised to $68-70M; adjusted EBITDA $3-4M.
- Preliminary 2024 revenue guidance of at least $110M; adjusted EBITDA margin at least 10%.
- Completed acquisition of Medicx Health post-Q3; total DAAP deals now at 16 for 2023.
- Cash and investments $63.5M as of Sep 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/0001213900-23-083645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023083645/ea187745-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-083645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer